In yesterday’s Wall Street session, Alzamend Neuro Inc. (NASDAQ:ALZN) shares traded at $0.53, down -11.31% from the previous session.
As of this writing, 1 analysts cover Alzamend Neuro Inc. (NASDAQ:ALZN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $7.00, we find $7.00. Given the previous closing price of $0.60, this indicates a potential upside of 1066.67 percent. ALZN stock price is now -50.08% away from the 50-day moving average and -48.73% away from the 200-day moving average. The market capitalization of the company currently stands at $52.67M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 0 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $7.00 as their price target over the next twelve months.
With the price target of $8, Ascendiant Capital Markets recently initiated with Buy rating for Alzamend Neuro Inc. (NASDAQ: ALZN).
In other news, AULT MILTON C III, 10% Owner bought 5,000 shares of the company’s stock on Dec 21. The stock was bought for $4,049 at an average price of $0.81. Upon completion of the transaction, the 10% Owner now directly owns 11,046,001 shares in the company, valued at $5.85 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 19, 10% Owner AULT MILTON C III bought 23,000 shares of the business’s stock. A total of $18,813 was incurred on buying the stock at an average price of $0.82. This leaves the insider owning 11,041,001 shares of the company worth $5.85 million. Insiders disposed of 102,016 shares of company stock worth roughly $54068.48 over the past 1 year. A total of 2.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ALZN stock. A new stake in Alzamend Neuro Inc. shares was purchased by BLACKROCK INC. during the first quarter worth $316,000. NORTHERN TRUST CORP invested $23,000 in shares of ALZN during the first quarter. In the first quarter, DARK FOREST CAPITAL MANAGEMENT LP acquired a new stake in Alzamend Neuro Inc. valued at approximately $6,000. BENJAMIN EDWARDS INC acquired a new stake in ALZN for approximately $1,000. In total, there are 23 active investors with 8.20% ownership of the company’s stock.
Wednesday morning saw Alzamend Neuro Inc. (NASDAQ: ALZN) opened at $0.6150. During the past 12 months, Alzamend Neuro Inc. has had a low of $0.58 and a high of $2.44. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.30, and a quick ratio of 6.30. The fifty day moving average price for ALZN is $1.0617 and a two-hundred day moving average price translates $1.0337 for the stock.
The latest earnings results from Alzamend Neuro Inc. (NASDAQ: ALZN) was released for Jul, 2022. According to the Biotechnology Company, earnings per share came in at -$0.03, beating analysts’ expectations of -$0.07 by 0.04. This compares to -$0.04 EPS in the same period last year. The company reported revenue of $3.11 million for the quarter, compared to $3.58 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.34 percent.
Alzamend Neuro Inc.(ALZN) Company Profile
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company’s pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
